- Home
- ZNTL vs ABOS Comparison
ZNTL vs ABOS Comparison
Compare ZNTL & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | ABOS |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 155.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | ABOS |
|---|---|---|
| Price | $2.72 | $3.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $6.60 | ★ $7.75 |
| AVG Volume (30 Days) | ★ 646.8K | 400.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.87 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,425,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $0.86 |
| 52 Week High | $3.95 | $3.60 |
Technical Indicators
Market Signals| Indicator | ZNTL | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 54.44 |
| Support Level | $1.29 | $1.26 |
| Resistance Level | $3.95 | N/A |
| Average True Range (ATR) | 0.22 | 0.29 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 50.00 | 41.41 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.